November 5, 2023
Runners will take on the marathon to support CMT research.
If you are interested in participating please email [email protected].
Helixmith, specializing in gene therapy research for over 20 years, has kicked off its phase I and 2a clinical trial for using VM202 (Engensis) to treat CMT1A.
US Food and Drug Administration has agreed with Pharnext and provided clear guidance on the regulatory pathway to approval for PXT3003, including key design elements of a single pivotal Phase III study
treatment with ACE-083 in patients with Charcot-Marie-Tooth disease (CMT) did not demonstrate functional improvement in the Phase 2 trial
Welcome and Opening Remarks Overview: What is CMT? - Michael Shy, MD Overview: What is CMT? - Dr....
HNF successfully executed the Externally-led PFDD Meeting for the FDA on September 28th, 2018.
HNF will be holding a landmark externally-led Patient-Focused Drug Development Meeting for CMT and INs in Washington, D.C. on Friday, September 28, 2018.
2018 will be “the year” for our community as we prepare for the externally-led Patient-Focused Drug Development Meeting.
Help support this ground-breaking PFDD CMT Meeting being held on September 28, 2018 in Washington, D.C.
HNF will be holding a landmark externally-led Patient-Focused Drug Development (PFDD) Meeting CMT & INs in Washington, D.C. on September 28, 2018. The meeting will be held in conjunction with September National CMT Awareness Month.
Pharnext completed patient enrollment for the international Phase 3 clinical trial of PXT3003, Pharnext’s lead PLEODRUG ©, for treatment of CMT1A.
0 Comments